

Pre - PA Allowance

None

Prior-Approval Requirements

Age 6 years of age or older

Diagnosis

Patient must have the following:

Cystic fibrosis (CF)

AND ALL of the following

1. Homozygous for the F508del mutation or at least one mutation in the CFTR gene that is responsive to Symdeko (see Appendix 2)
2. Pretreatment percent predicted forced expiratory volume (ppFEV₁) must be provided
3. Baseline ALT, AST, and bilirubin must be obtained at baseline and tested every 3 months for the first year
4. Must be prescribed by a pulmonologist or gastroenterologist
5. **NO** dual therapy with another cystic fibrosis transmembrane conductance regulator (CFTR) potentiator (see Appendix 1)

Prior - Approval Limits

Quantity 168 tablets for 84 days

Duration 6 months

Prior – Approval *Renewal* Requirements

Age 6 years of age or older

Diagnosis

Patient must have the following:

Cystic Fibrosis (CF)

SYMDEKO
(tezacaftor and ivacaftor)

AND ALL of the following:

1. Stable or improvement of ppFEV₁ from baseline
2. Annual testing of ALT, AST, and bilirubin levels after the first year of therapy
3. **NO** dual therapy with another cystic fibrosis transmembrane conductance regulator (CFTR) potentiator (see Appendix 1)

Prior - Approval *Renewal* Limits

Quantity 168 tablets for 84 days

Duration 12 months

Appendix 1 - List of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiators

Generic Name	Brand Name
ivacaftor	Kalydeco
ivacaftor/lumacaftor	Orkambi
ivacaftor/tezacaftor	Symdeko
ivacaftor/tezacaftor/elexacaftor	Trikafta

Appendix 2 - List of *CFTR* Gene Mutations that are Responsive to Symdeko

546insCTA	E92K	G576A	L346P	R117G	S589N
711+3A→G	E116K	G576A;R668 C †	L967S	R117H	S737F
2789+5G→A	E193K	G622D	L997F	R117L	S912L
3272-26A→G	E403D	G970D	L1324P	R117P	S945L
3849+10kbC→T	E588V	G1069R	L1335P	R170H	S977F
A120T	E822K	G1244E	L1480P	R258G	S1159 F
A234D	E831X	G1249R	M152V	R334L	S1159 P
A349V	F191V	G1349D	M265R	R334Q	S1251 N
A455E	F311del	H939R	M952I	R347H	S1255 P
A554E	F311L	H1054D	M952T	R347L	T338I

SYMDEKO
(tezacaftor and ivacaftor)

A1006E	F508C	H1375P	P5L	R347P	T1036 N
A1067T	F508C;S1251 N †	I148T	P67L	R352Q	T1053I
D110E	F508del ^	I175V	P205S	R352 W	V201M
D110H	F575Y	I336K	Q98R	R553Q	V232D
D192G	F1016S	I601F	Q237E	R668C	V562I
D443Y	F1052V	I618T	Q237H	R751L	V754M
D443Y;G576A;R6 68C †	F1074L	I807M	Q359R	R792G	V1153 E
D579G	F1099L	I980K	Q1291R	R933G	V1240 G
D614G	G126D	I1027T	R31L	R1066 H	V1293 G
D836Y	G178E	I1139V	R74Q	R1070 Q	W1282 R
D924N	G178R	I1269N	R74W	R1070 W	Y109N
D979V	G194R	I1366N	R74W;D1270N †	R1162 L	Y161S
D1152H	G194V	K1060T	R74W;V201M †	R1283 M	Y1014 C
D1270N	G314E	L15P	R74W;V201M;D12 70N †	R1283 S	Y1032 C
E56K	G551D	L206W	R75Q	S549N	
E60K	G551S	L320V	R117C	S549R	
^ A patient must have two copies of the <i>F508del</i> mutation or at least one copy of a responsive mutation presented above to be indicated. † Complex/compound mutations where a single allele of the <i>CFTR</i> gene has multiple mutations; these exist independent of the presence of mutations on the other allele.					